- Short Report
- Open Access
In vitro evaluation of β-carboline alkaloids as potential anti-Toxoplasma agents
- Maria L Alomar1,
- Federico AO Rasse-Suriani2,
- Agustina Ganuza1,
- Verónica M Cóceres1,
- Franco M Cabrerizo†2Email author and
- Sergio O Angel†1Email author
© Alomar et al.; licensee BioMed Central Ltd. 2013
- Received: 18 December 2012
- Accepted: 7 May 2013
- Published: 10 May 2013
Toxoplasmosis is a worldwide infection caused by the protozoan parasite Toxoplasma gondii, which causes chorioretinitis and neurological defects in congenitally infected newborns or immunodeficient patients. The efficacy of the current treatment is limited, primarily by serious host toxicity. In recent years, research has focused on the development of new drugs against T. gondii. β-Carbolines (βCs), such as harmane, norharmane and harmine, are a group of naturally occurring alkaloids that show microbicidal activity. In this work, harmane, norharmane and harmine were tested against T. gondii.
The treatment of extracellular tachyzoites with harmane, norharmane and harmine showed a 2.5 to 3.5-fold decrease in the invasion rates at doses of 40 μM (harmane and harmine) and 2.5 μM (norharmane) compared with the untreated parasites. Furthermore, an effect on the replication rate could also be observed with a decrease of 1 (harmane) and 2 (norharmane and harmine) division rounds at doses of 5 to 12.5 μM. In addition, the treated parasites presented either delayed or no monolayer lysis compared with the untreated parasites.
The three βC alkaloids studied (norharmane, harmane and harmine) exhibit anti-T. gondii effects as evidenced by the partial inhibition of parasite invasion and replication. A dose–response effect was observed at a relatively low drug concentration (< 40 μM), at which no cytotoxic effect was observed on the host cell line (Vero).
- Toxoplasma gondii
- Cell cycle
The protozoan parasite Toxoplasma gondii is the etiologic agent of toxoplasmosis, a worldwide infection affecting 500 million to 1 billion people . Toxoplasmosis occurs as an asymptomatic chronic (latent) infection. However, it is of medical health importance because toxoplasmosis can be dangerous or even fatal in immunocompromised individuals because of the reactivation of a latent infection. Congenital infection with Toxoplasma can also cause either spontaneous abortion or birth defects . In the latter case, the active form of the parasite can cause encephalitis and neurologic diseases and can affect the heart, liver, inner ears, and eyes (chorioretinitis). Recently, chronic toxoplasmosis has been linked with brain cancer, attention deficit hyperactivity disorder, obsessive-compulsive disorder and schizophrenia [3–6].
There are effective drug regimens for toxoplasmosis based on a combination of pyrimethamine and sulfadiazine, but in some cases the efficacy of the current treatment is limited, primarily by serious host toxicity and/or development of drug-resistant parasites. In patients under immunosuppressive therapies and particularly in those with AIDS, treatment with sulfonamides and inhibitors of dihydrofolate reductase (DHFR) can produce side effects despite the preventive administration of folinic acid [7, 8]. Moreover, the current therapy is ineffective against tissue cysts . Other therapies, based on other types of drugs (clindamycin, spiramycin or atovaquone), have been used with limited success particularly in long-term patient management.
βCs were originally isolated from Peganumharmala (Zygophyllaceae, Syrian Rue), which is used as a traditional herbal drug [19, 20]. Among them, harmane and tetrahydroharmane isolated from active extracts of different plants have been shown to have antimalarial activity and low cytotoxicity for human cells [21–23]. In addition, harmane and harmine have been shown a moderate effect on promastigotes of Leishmania infantum, mainly by accumulation of parasites arrested in the S-G2/M phases of the cell cycle, whereas harmaline has shown only anti-leishmanial activity against intracellular amastigotes by inhibiting the PKC enzyme . Lala et al.  have shown that harmine is toxic for the promastigotes of Leishmania donovani, an effect attributed to necrosis due to non-specific membrane damage. The nifurtimox-resistant Trypanosoma cruzi LQ strain has shown a greater sensitivity to βCs, most likely due to inhibition of the respiratory chain of the parasite . The chaperone HSP90 is an important drug target in protozoan parasites and new drugs are actively being sought [12, 27]. In this regard, harmine was one of the three compounds selected among approximately 4,000 small molecules that inhibited P. falciparum HSP90 by specific competition with its ATP-binding domain. Interestingly, harmine has been shown to have anti-malarial effects in vitro and in vivo and acts synergistically with chloroquine and artemisinin [28, 29]. El Sayed et al.  also reported that new enantiomers of 8-hydroxymanzamine A (ent-8-hydroxymanzamine A) and manzamine F (entmanzamine), isolated from Indo-Pacific sponge, together with manzamine A, exhibit significant activities against T. gondii and Plasmodium spp. There are also other studies in which βCs have shown parasiticidal and microbicidal effects that were further revised by Cao et al. .
The success of T. gondii infection relies on host cell recognition and attachment, invasion, replication and egress to spread throughout the host organism. Therefore, blocking any of these processes represents a target for new anti-Toxoplasma drugs/therapies. Our laboratory has gained experience in the analysis of harmane, norharmane and harmine for different purposes including their use as anti-viral drugs (Cabrerizo et al., unpublished results). The biological and pharmacological effects of these βCs are attributed in part to their ability to intercalate DNA and inhibit topoisomerase I and II, effects that result in alterations in DNA replication and, therefore, defects in cell cycle progress . In addition, harmine has been found to be a potent and specific inhibitor of cyclin-dependent kinases (CDKs), showing a strong inhibitory effect on the growth and proliferation of carcinoma cells [31, 32]. In this work, we evaluated these three βC alkaloids, harmane, norharmane and harmine, for their potential as new drugs against T. gondii, based on their ability to block invasion, replication and growth processes.
Norharmane, harmane, harmine and sulfadiazine (Sigma-Aldrich Co., Buenos Aires, Argentina) were of the highest purity available (> 98%) and used without further purification.
Stock solutions preparation and pH adjustment
βC stock solutions (approximately 2 mM) were prepared as described elsewhere . Briefly, each alkaloid was dissolved in acid-sterilized water. Once the alkaloid was fully dissolved, the pH of the aqueous solutions was adjusted to 7.4 by the addition of drops of HCl or NaOH solutions from a micropipette. The aliquots used in the in vitro experiments did not modify the pH of the cell culture. Sulfadiazine was dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich Co.) at 22 mM.
Parasite sources, culture and manipulation
Tachyzoites of the RH strain were cultured in standard tachyzoite conditions in vitro: Vero and human foreskin fibroblast (HFF) cell monolayers were infected with tachyzoites and incubated with Dulbecco’s modified Eagle medium (DMEM, Gibco BRL) supplemented with 10% fetal bovine serum (FBS), penicillin (100 UI/ml; Gibco BRL) and streptomycin (100 μg/ml; Gibco BRL) at 37°C and 5% CO2.
Tachyzoites of the RH strain (2.5×106) were incubated for 1 h with different doses of βCs or water (untreated) in DMEM at 37°C. Treated and untreated tachyzoites were added to a Vero cell monolayer, incubated for 10 min on ice and then incubated at 37°C for 1 h, washed three times with PBS and fixed with 4% paraformaldehyde and 0.2% Triton X-100 and analyzed by immunofluorescence using murine anti-SAG1 antibody (SAG1: T. gondii surface antigen 1, 1:100 dilution)/Alexa Fluor 594-conjugated goat anti-mouse (1:4,000 dilution; Invitrogen, Argentina). In each experiment, 50 fields were analyzed and the number of tachyzoites per field was counted. Only fields with a similar number of host cells were considered for the experiments. The mean numbers of tachyzoites in each field plus the standard deviation were plotted using Prism GraphPad software.
Replication and growth analysis
The replication rate was determined by incubating the tachyzoites (2.5×106) with Vero cell monolayers, followed by 10 min of incubation on ice, then 1 h at 37°C and washing three times with PBS. Finally, the tachyzoites were incubated for an additional 24 h at 37°C, 5% CO2 with DMEM, 5% FBS and different doses of βCs or water (untreated). After the infected monolayers were fixed, they were immunolabeled with murine anti-SAG1 antibody/Alexa Fluor 594-conjugated goat anti-mouse antibody (Invitrogen, Argentina) and the number of tachyzoites per parasitophorous vacuole (PV) were counted. Fifty fields were counted in duplicate. Approximately 1000 PVs were counted at each dose. Data are presented as a percentage of PVs that contained a geometric progression (e.g. 1, 2, 4, 8 and so on) of tachyzoites per PV.
To analyze parasite growth, human foreskin fibroblast (HFF) monolayers were incubated with 2×104 tachyzoites as above mentioned. Because tachyzoite growth is destructive to cell monolayers, infected cultures were followed daily by inverted microscope visualization until complete monolayer lysis along with the presence of extracellular tachyzoites or complete (host cell/tachyzoites) destruction.
To determine whether these βCs have any inhibitory effect on the parasite cycle process, we measured the ability of intracellular-treated parasites to replicate. Because tachyzoites replicate only within the host cell by a process called endodyogeny, every round of replication results in a geometric duplication of the parasite number per PV (e.g. 1, 2, 4, 8 and so on) . Monolayers of Vero cells were infected with 2.5×106 of fresh tachyzoites to allow for the formation of PVs. Subsequently, the infected monolayers were washed and incubated at 37°C for 24 h in the presence of different doses of βCs (0 to 40 μM) (Figure 2B). Every PV was generated from one parasite; therefore, the number of tachyzoites inside the PV indicates the number of replication events. The panel shows the percentage of PVs that presented different numbers of tachyzoites. Harmane showed a slight inhibitory effect starting at 25 μM, resulting in a delay of one round of replication compared with the untreated parasites. Harmine and norharmane had a stronger inhibitory effect on parasite replication than harmane, because their effect was more pronounced at 25 μM, at which concentration the replication rate was delayed by two rounds (Figure 2B). Doses of norharmane lower than 5 μM did not show any effect on parasite replication (Additional file 1: Figure S1).
Our results demonstrate that the three βCs studied in this work have anti-T. gondii effects on both host cell invasion and replication processes and, consequently, on parasite growth. Particularly, harmine was shown to be the most active drug because it showed the strongest inhibitory effect on parasite replication and growth. In a recent study , it has been observed that harmine shows anti-leishmanial activity in part due to cell death attributed to non-specific membrane damage. In our hands, the highest dose (40 μM) of βCs affected neither the cell integrity nor the viability of the parasite. The entry of the tachyzoite into the host cell is an ATP-consuming process that includes the glideosome/myosin motor . In this sense, some βCs have shown an inhibitory effect of the respiratory chain [26, 37]. It is possible that parasite fitness is decreased because of a failure of mitochondrial functions. Our analysis did not allow us to distinguish which process (es) these drugs were affecting (attachment and/or invasion). Therefore, the βCs could be interfering with several metabolism pathways other than those related to attachment/invasion of the host cell, resulting in an impairment of these processes. Further analysis should be performed to elucidate which process/es is/are involved.
As mentioned above, βCs are considered to affect cell cycle. The tachyzoite is the highly replicative stage of T. gondii, a process that only occurs inside the host cell . It is well known that these drugs can bind to DNA  and induce DNA damage  as well as inhibit topoisomerases I and II. These facts can contribute to the replication-associated DNA stress, affecting the cell replication rate [41, 42]. Harmine also affects Plasmodium infection through its interaction with parasite HSP90, a recognized drug target against malaria [12, 29]. The effect of this (or these) βC(s) on parasite replication could also involve the inhibition of Toxoplasma HSP90 functions. In fact, T. gondii HSP90 has been suggested as a key molecule in parasite replication . Future studies should be performed to assess the interaction between these alkaloids and T. gondii topoisomerases and/or HSP90 protein and evaluate if these drugs can affect parasite cell cycle progression.
In conclusion, we have demonstrated that the three βC alkaloids studied (norharmane, harmane and harmine) exhibit anti-T. gondii effects. Interestingly, the effect on parasite invasion and replication occurred at low doses (below 40 μM), at which these alkaloids did not show any toxic effects on Vero and HFF cells used in our experiments [32, 34]. However, βCs have been shown to inhibit some enzymes associated with mental disorders and could produce behavioral modifications, including hallucinogens in treated people . This issue should be considered to determine in vivo doses . Moreover, on the basis of the current knowledge , it would be possible to design novel harmine derivatives to avoid collateral effects without changing or even increasing the parasiticidal effect. Future studies should be performed to further elucidate the mechanism for their anti-T. gondii activity.
S. O. Angel (Researcher), F. M. Cabrerizo (Researcher), M. L. Alomar (Fellow), V. M. Cóceres (Fellow) and F. A. O. Rasse-Suriani (Fellow) are members of the National Research Council of Argentina (CONICET). A. Ganuza is a member of CIC (Province of Buenos Aires, Argentina). This work was supported by ANPCyT grant BID ‒ PICT 2011–0623 (to S. O. A.); NIH-NIAID 1R01AI083162-01 (to S. O. A.) and PIP-00400 (to F. M. C.). We are grateful to Alejandra Goldman and Valentina Martin for their critical readings of the manuscript.
- Tenter AM, Heckeroth AR, Weiss LM: Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000, 30 (12–13): 1217-1258.PubMedPubMed CentralView ArticleGoogle Scholar
- Carlier Y, Truyens C, Deloron P, Peyron F: Congenital parasitic infections: a review. Acta Trop. 2012, 121 (2): 55-70. 10.1016/j.actatropica.2011.10.018.PubMedView ArticleGoogle Scholar
- Brynska A, Tomaszewicz-Libudzic E, Wolanczyk T: Obsessive-compulsive disorder and acquired toxoplasmosis in two children. Eur Child Adolesc Psychiatry. 2001, 10 (3): 200-204. 10.1007/s007870170027.PubMedView ArticleGoogle Scholar
- Miman O, Mutlu EA, Ozcan O, Atambay M, Karlidag R, Unal S: Is there any role of Toxoplasma gondii in the etiology of obsessive-compulsive disorder?. Psychiatry Res. 2010, 177 (1–2): 263-265.PubMedView ArticleGoogle Scholar
- Yolken RH, Dickerson FB, Fuller Torrey E: Toxoplasma and schizophrenia. Parasite Immunol. 2009, 31 (11): 706-715. 10.1111/j.1365-3024.2009.01131.x.PubMedView ArticleGoogle Scholar
- Vittecoq M, Elguero E, Lafferty KD, Roche B, Brodeur J, Gauthier-Clerc M, Misse D, Thomas F: Brain cancer mortality rates increase with Toxoplasma gondii seroprevalence in France. Infect Genet Evol. 2012, 12 (2): 496-498. 10.1016/j.meegid.2012.01.013.PubMedView ArticleGoogle Scholar
- Luft BJ, Remington JS: Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992, 15 (2): 211-222. 10.1093/clinids/15.2.211.PubMedView ArticleGoogle Scholar
- Wong SY, Remington JS: Biology of Toxoplasma gondii. AIDS. 1993, 7 (3): 299-316. 10.1097/00002030-199303000-00001.PubMedView ArticleGoogle Scholar
- Weiss LM, Kim K: The development and biology of bradyzoites of Toxoplasma gondii. Front Biosci. 2000, 5: D391-405. 10.2741/Weiss.PubMedPubMed CentralView ArticleGoogle Scholar
- Rodriguez JB, Szajnman SH: New antibacterials for the treatment of toxoplasmosis; a patent review. Expert Opin Ther Pat. 2012, 22 (3): 311-333. 10.1517/13543776.2012.668886.PubMedView ArticleGoogle Scholar
- Vanagas L, Jeffers V, Bogado SS, Dalmasso MC, Sullivan WJ, Angel SO: Toxoplasma histone acetylation remodelers as novel drug targets. Expert Rev Anti Infect Ther. 2012, 10 (10): 1189-1201. 10.1586/eri.12.100.PubMedPubMed CentralView ArticleGoogle Scholar
- Angel SO, Matrajt M, Echeverria PC: A review of recent patents on the protozoan parasite HSP90 as a drug target. 2012, Biotechnol: Recent PatGoogle Scholar
- Herraiz T, Gonzalez D, Ancin-Azpilicueta C, Aran VJ: Guillen H: beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol. 2010, 48 (3): 839-845. 10.1016/j.fct.2009.12.019.PubMedView ArticleGoogle Scholar
- Pfau W, Skog K: Exposure to beta-carbolines norharman and harman. J Chromatogr B Analyt Technol Biomed Life Sci. 2004, 802 (1): 115-126. 10.1016/j.jchromb.2003.10.044.PubMedView ArticleGoogle Scholar
- Pari K, Sundari CS, Chandani S: Balasubramanian D: beta-carbolines that accumulate in human tissues may serve a protective role against oxidative stress. J Biol Chem. 2000, 275 (4): 2455-2462. 10.1074/jbc.275.4.2455.PubMedView ArticleGoogle Scholar
- Spijkerman R, van den Eijnden R, van de Mheen D, Bongers I, Fekkes D: The impact of smoking and drinking on plasma levels of norharman. Eur Neuropsychopharmacol. 2002, 12 (1): 61-71. 10.1016/S0924-977X(01)00143-2.PubMedView ArticleGoogle Scholar
- Torreilles J, Guerin MC, Previero A: Simple compounds with high pharmacologic potential: beta-carbolines. Origins, syntheses, biological properties. Biochimie. 1985, 67 (9): 929-947. 10.1016/S0300-9084(85)80289-3.PubMedView ArticleGoogle Scholar
- Gonzalez MM, Arnbjerg J, Denofrio MP, Erra-Balsells R, Ogilby PR, Cabrerizo FM: One- and two-photon excitation of beta-carbolines in aqueous solution: pH-dependent spectroscopy, photochemistry, and photophysics. J Phys Chem A. 2009, 113 (24): 6648-6656. 10.1021/jp902105x.PubMedView ArticleGoogle Scholar
- Sobhani AM, Ebrahimi SA, Mahmoudian M: An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids. J Pharm Pharm Sci. 2002, 5 (1): 19-23.PubMedGoogle Scholar
- Cao R, Peng W, Wang Z, Xu A: beta-Carboline alkaloids: biochemical and pharmacological functions. Curr Med Chem. 2007, 14 (4): 479-500. 10.2174/092986707779940998.PubMedView ArticleGoogle Scholar
- Azas N, Laurencin N, Delmas F, Di GC, Gasquet M, Laget M, Timon-David P: Synergistic in vitro antimalarial activity of plant extracts used as traditional herbal remedies in Mali. Parasitol Res. 2002, 88 (2): 165-171. 10.1007/s004360100454.PubMedView ArticleGoogle Scholar
- Ancolio C, Azas N, Mahiou V, Ollivier E, Di Giorgio C, Keita A, Timon-David P, Balansard G: Antimalarial activity of extracts and alkaloids isolated from six plants used in traditional medicine in Mali and Sao Tome. Phytother Res. 2002, 16 (7): 646-649. 10.1002/ptr.1025.PubMedView ArticleGoogle Scholar
- Fiot J, Jansen O, Akhmedjanova V, Angenot L, Balansard G, Ollivier E: HPLC quantification of alkaloids from Haplophyllum extracts and comparison with their cytotoxic properties. Phytochem Anal. 2006, 17 (5): 365-369. 10.1002/pca.927.PubMedView ArticleGoogle Scholar
- Di Giorgio C, Delmas F, Ollivier E, Elias R, Balansard G, Timon-David P: In vitro activity of the beta-carboline alkaloids harmane, harmine, and harmaline toward parasites of the species Leishmania infantum. Exp Parasitol. 2004, 106 (3–4): 67-74.PubMedView ArticleGoogle Scholar
- Lala S, Pramanick S, Mukhopadhyay S, Bandyopadhyay S, Basu MK: Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J Drug Target. 2004, 12 (3): 165-175. 10.1080/10611860410001712696.PubMedView ArticleGoogle Scholar
- Rivas P, Cassels BK, Morello A, Repetto Y: Effects of some beta-carboline alkaloids on intact Trypanosoma cruzi epimastigotes. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1999, 122 (1): 27-31. 10.1016/S0742-8413(98)10069-5.PubMedView ArticleGoogle Scholar
- Rochani AK, Singh M, Tatu U: Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-infectives. Curr Pharm Des. 2012Google Scholar
- Shahinas D, Liang M, Datti A, Pillai DR: A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem. 2010, 53 (9): 3552-3557. 10.1021/jm901796s.PubMedView ArticleGoogle Scholar
- Shahinas D, Macmullin G, Benedict C, Crandall I, Pillai DR: Harmine is a potent antimalarial targeting Hsp90 and synergizes with chloroquine and artemisinin. Antimicrob Agents Chemother. 2012, 56 (8): 4207-4213. 10.1128/AAC.00328-12.PubMedPubMed CentralView ArticleGoogle Scholar
- El Sayed KA, Kelly M, Kara UA, Ang KK, Katsuyama I, Dunbar DC, Khan AA, Hamann MT: New manzamine alkaloids with potent activity against infectious diseases. J Am Chem Soc. 2001, 123 (9): 1804-1808. 10.1021/ja002073o.PubMedView ArticleGoogle Scholar
- Song Y, Wang J, Teng SF, Kesuma D, Deng Y, Duan J, Wang JH, Qi RZ, Sim MM: β-Carbolines as specific inhibitors of cyclin-Dependent kinases. Bioorg Med Chem Lett. 2002, 12 (7): 1129-1132. 10.1016/S0960-894X(02)00094-X.PubMedView ArticleGoogle Scholar
- Song Y, Kesuma D, Wang J, Deng Y, Duan J, Wang JH, Qi RZ: Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem Biophys Res Commun. 2004, 317 (1): 128-132. 10.1016/j.bbrc.2004.03.019.PubMedView ArticleGoogle Scholar
- Gonzalez MM, Salum ML, Gholipour Y, Cabrerizo FM, Erra-Balsells R: Photochemistry of norharmane in aqueous solution. Photochem Photobiol Sci. 2009, 8 (8): 1139-1149. 10.1039/b822173a.PubMedView ArticleGoogle Scholar
- Jimenez J, Riveron-Negrete L, Abdullaev F, Espinosa-Aguirre J, Rodriguez-Arnaiz R: Cytotoxicity of the beta-carboline alkaloids harmine and harmaline in human cell assays in vitro. Exp Toxicol Pathol. 2008, 60 (4–5): 381-389.PubMedView ArticleGoogle Scholar
- Striepen B, Jordan CN, Reiff S, van Dooren GG: Building the perfect parasite: cell division in apicomplexa. PLoS Pathog. 2007, 3 (6): e78-10.1371/journal.ppat.0030078.PubMedPubMed CentralView ArticleGoogle Scholar
- Baum J, Papenfuss AT, Baum B, Speed TP, Cowman AF: Regulation of apicomplexan actin-based motility. Nat Rev Microbiol. 2006, 4 (8): 621-628. 10.1038/nrmicro1465.PubMedView ArticleGoogle Scholar
- Bringmann G, Feineis D, Bruckner R, Blank M, Peters K, Peters EM, Reichmann H, Janetzky B, Grote C, Clement HW: Bromal-derived tetrahydro-beta-carbolines as neurotoxic agents: chemistry, impairment of the dopamine metabolism, and inhibitory effects on mitochondrial respiration. Bioorg Med Chem. 2000, 8 (6): 1467-1478. 10.1016/S0968-0896(00)00073-0.PubMedView ArticleGoogle Scholar
- Radke JR, Striepen B, Guerini MN, Jerome ME, Roos DS, White MW: Defining the cell cycle for the tachyzoite stage of Toxoplasma gondii. Mol Biochem Parasitol. 2001, 115 (2): 165-175. 10.1016/S0166-6851(01)00284-5.PubMedView ArticleGoogle Scholar
- Gonzalez MM, Vignoni M, Pellon-Maison M, Ales-Gandolfo MA, Gonzalez-Baro MR, Erra-Balsells R, Epe B, Cabrerizo FM: Photosensitization of DNA by beta-carbolines: kinetic analysis and photoproduct characterization. Org Biomol Chem. 2012, 10 (9): 1807-1819. 10.1039/c2ob06505c.PubMedView ArticleGoogle Scholar
- Gonzalez MM, Pellon-Maison M, Ales-Gandolfo MA, Gonzalez-Baro MR, Erra-Balsells R, Cabrerizo FM: Photosensitized cleavage of plasmidic DNA by norharmane, a naturally occurring beta-carboline. Org Biomol Chem. 2010, 8 (11): 2543-2552. 10.1039/c002235g.PubMedView ArticleGoogle Scholar
- Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989, 49 (18): 5077-5082.PubMedGoogle Scholar
- D'Arpa P, Beardmore C, Liu LF: Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 1990, 50 (21): 6919-6924.PubMedGoogle Scholar
- Echeverria PC, Matrajt M, Harb OS, Zappia MP, Costas MA, Roos DS, Dubremetz JF, Angel SO: Toxoplasma gondii Hsp90 is a potential drug target whose expression and subcellular localization are developmentally regulated. J Mol Biol. 2005, 350 (4): 723-734. 10.1016/j.jmb.2005.05.031.PubMedView ArticleGoogle Scholar
- Reniers J, Robert S, Frederick R, Masereel B, Vincent S, Wouters J: Synthesis and evaluation of beta-carboline derivatives as potential monoamine oxidase inhibitors. Bioorg Med Chem. 2011, 19 (1): 134-144. 10.1016/j.bmc.2010.11.041.PubMedView ArticleGoogle Scholar